
1	Novel Human Lung Tissue Model for the Study of SARS-CoV-2 Entry,
2	Inflammation and New Therapeutics
3	
4	Judith Grau-Expósito ¹ *, David Perea ¹ *, Marina Suppi ¹ , Núria Massana ¹ , Ander Vergara ² , Maria
5	José Soler ² , Javier García-Pérez ³ , José Alcamí ^{3,4} , Anna Serrano-Mollar ^{5,6} , Joel Rosado ⁷ , Vicenç
6	Falcó ¹ , Meritxell Genescà ¹ *, and Maria J. Buzon ¹ *
7	¹ Infectious Diseases Department, Vall d'Hebron Research Institute (VHIR), Hospital Universitari
8	Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. VHIR Task Force COVID-
9	19.
10	² Nephrology Research Department, Vall d'Hebron Research Institute (VHIR), Hospital
11	Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. VHIR Task
12	Force COVID-19.
13	³ AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III,
14	Madrid, Spain.
15	⁴ Clinic HIV Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain.
16	⁵ Experimental Pathology Department, Institut d'Investigacions Biomèdiques de Barcelona,
17	Consejo Superior de Investigaciones Científicas (IIBB-CSIC), Institut d'Investigacions
18	Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
19	⁶ Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES),
20	Madrid, Spain.
21	⁷ Thoracic Surgery and Lung Transplantation Department, Vall d'Hebron Institut de Recerca
22	(VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain. VHIR Task Force COVID-19.
23	Running title: Human lung for the study of SARS-CoV-2
24	Corresponding authors*: Maria J. Buzon (mariajose.buzon@vhir.org) and Meritxell Genescà
25	(meritxell.genesca@vhir.org)

26 Abstract

The development of physiological models that reproduce SARS-CoV-2 infection in primary 27 28 human cells will be instrumental to identify host-pathogen interactions and potential 29 therapeutics. Here, using cell suspensions from primary human lung tissues (HLT), we have 30 developed a platform for the identification of viral targets and the expression of viral entry 31 factors, as well as for the screening of viral entry inhibitors and anti-inflammatory compounds. We show that the HLT model preserves its main cell populations, maintains the expression of 32 33 proteins required for SARS-CoV-2 infection, and identifies alveolar type II (AT-II) cells as the most 34 susceptible cell targets for SARS-CoV-2 in the human lung. Antiviral testing of 39 drug candidates revealed a highly reproducible system, and provided the identification of new compounds 35 36 missed by conventional systems such as VeroE6. Using this model, we also show that interferons 37 do not modulate ACE2 expression, and that stimulation of local inflammatory responses can be 38 modulated by different compounds with antiviral activity. Overall, we present a novel and relevant physiological model for the study of SARS-CoV-2. 39

40 Synopsis



41

42 *Ex vivo* physiological systems for the study of SARS-CoV-2-host interactions are scarce. Here, we

establish a novel model using primary human lung tissue (HLT) for the analysis of cell tropismand identification of therapeutics.

- The HLT model preserves main cell subpopulations, including alveolar type-2 cells, and expression of SARS-CoV-2 entry factors ACE2, CD147, and TMPRSS2.
 The HLT model is readily susceptible to SARS-CoV-2 entry.
- Antiviral testing in the HLT model allows the identification of new candidates missed
 by conventional systems.
- Local inflammation is supported in the HLT model and offers the identification of
 relevant anti-inflammatory compounds for SARS-CoV-2 infection.

52 Introduction

53 We are facing a global health emergency, the COVID-19 pandemic, caused by the novel SARS-54 CoV-2 virus. There is currently no specific treatment to cure SARS-CoV-2 infection to limit disease 55 progression of associated COVID-19. Early clinical trials showed promising drug candidates; 56 remdesivir, a compound that inhibits the RNA synthesis of SARS-CoV-2, was superior to placebo 57 in shortening the time to recovery in adults who were hospitalized with COVID-19 [1], however, 58 the Solidarity trial failed to support this observation [2]. Recently, plitidepsin, a molecule that 59 targets the eEF1A host protein has shown potent preclinical efficacy against SARS-CoV-2 [3]. 60 Importantly, the development of Acute Respiratory Distress Syndrome in severe COVID-19 61 patients has been linked to dysregulated inflammatory responses. In this regard, the 62 glucocorticoid dexamethasone decreased 28-day mortality among patients receiving invasive mechanical ventilation, but no benefit was observed in patients without respiratory support [4]. 63 64 Thus, no effective treatment is currently available for COVID-19, and the rapid identification of 65 antivirals with the potential to be easily transferred into the clinic could save human lives.

Screening of novel drug candidates is often performed using cell lines. In this sense, the most 66 widely used cell lines for SARS-CoV-2 studies are epithelial cells derived either from lung (Calu-67 68 3), kidney (VeroE6), or colon (CaCo-2) [5]. These immortalized systems are highly reproducible 69 and easy to handle but lack physiological relevance. The differential gene expression profiling of 70 cell lines compared with primary cells from tissues might significantly affect important enzymes 71 involved in the viral replication cycle. For instance, the level of ACE2 expression, the main 72 receptor used by SARS-CoV-2 for viral entry, is shown to be different in several cell lines [6], 73 while only a small fraction of alveolar type II (AT-II) cells, the main target for SARS-CoV-2 in the 74 lung, express ACE2 [7, 8]. In addition, SARS-CoV-2 spike (S) glycoprotein, which is responsible for 75 viral entry into target cells, can be activated by several host proteases, such as furin, 76 transmembrane serine proteinase 2 (TMPRSS2) and cathepsin L, in a pH-dependent or 77 independent manner [9, 10]. Whereas in some cell lines S protein is activated by endosomal pH-78 dependent protease cathepsin L, in airway epithelial cells viral entry depends on the pH-79 independent TMPRSS2 protease [10]. Thus, it is currently not well defined if SARS-CoV-2 may 80 utilize multiple cell-type-specific host proteins for viral replication in primary target tissues and 81 therefore, the potency of therapeutics directed against these proteins may also differ.

Further, inflammatory immune responses might also impact viral dynamics in the lung by
affecting the expression of entry receptors. In this sense, early studies discovered that ACE2 was
a human interferon-stimulated gene (ISG); IFN-β and IFN-γ were shown to strongly upregulate

85 the expression of ACE2 at the mRNA and cell surface protein levels, indicating that inflammatory 86 molecules could shape cell susceptibility to viral infection [11]. However, how anti-inflammatory 87 drugs may affect ACE2 expression and facilitate SARS-CoV-2 infection remains to be elucidated. One study reported that the use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as 88 89 ibuprofen, was linked to enhanced ACE2 expression in a diabetic-induced rat model [12] and 90 other reports raised alarms regarding the possible role of NSAIDs at increasing susceptibility to 91 SARS-CoV-2 infection [13, 14]. On the contrary, experimental and clinical evidence show that medium-to-low-dose glucocorticoids may play a protective role in COVID-19 by activating ACE2 92 93 and suppressing the associated cytokine storm [15]. Overall, the use of more relevant and 94 physiological models for the study of either SARS-CoV-2 infection, the identification of drug 95 candidates, or the impact of new therapeutics on the disease could significantly advance the 96 successful translation of the results into the clinic.

97 Primary epithelial cell cultures of nasal and proximal airway epithelium have been used to study 98 SARS-CoV-2 infection in the upper airways [8, 16-18]. Similarly, organ on-chip and organoids 99 models of AT-II cells have been successfully developed [17, 19]. While very promising, these 100 models still miss certain aspects of cellular complexity present in primary tissues [20]. In this 101 regard, establishing a human lung tissue (HLT) model could offer a physiologically relevant 102 alternative to in vitro and in vivo approaches for several reasons; it mimics the main site of viral 103 replication in the lung, and contains all heterogeneous cell components present in the tissue 104 with greater functional complexity compared to cell lines. Although still representing a 105 reductionist ex vivo approach, it allows controlled experimental conditions. In the past, similar 106 lung models have been successfully established to study the effect of allergens and 107 inflammatory stimuli [21, 22]. Importantly, the HLT model allows mimicking an inflammatory 108 local response that could be attenuated by anti-inflammatory drugs [23]. Furthermore, it has 109 been used to provide low/medium throughput screening of anti-inflammatory candidate drugs 110 for the treatment of airway diseases [23]. Significantly, lung tissues not only can be infected with 111 SARS-CoV-2, but also generate local immune responses to viral infection [24]. Considering all 112 these factors, here we aimed to develop and characterize a physiological and reproducible human lung tissue model, which could be used for the study of virus-host interactions, 113 114 identification of potential antiviral compounds, as well as help investigating the role of 115 inflammation in relation to SARS-CoV-2 infection.

116 Results

117 Characterization of the HLT model

118 To establish the HLT model, non-neoplastic areas from lung tissue resections were obtained 119 from hospitalized non-COVID19 patients undergoing thoracic surgery. First, we optimized cell 120 culture and digestion conditions, since the methodology used for tissue processing can 121 significantly impact viability and function of target cell populations. Thus, we tested the 122 preservation of AT-II, defined mainly by EpCAM and HLA-DR expression [25], and of several 123 hematopoietic cell subsets, after tissue digestion with different enzymes. Flow cytometry gating 124 strategy and cell markers used for identification of main populations are shown in Figure S1A. 125 We observed that collagenase outperformed liberase and trypsin at preserving AT-II cells, the 126 main SARS-CoV-2 target (Figure S2A-B). Among the hematopoietic cells present in the lung 127 tissue we identified CD3 T (which represented 1.94% ± 0.59 out of the total live cell fraction), 128 myeloid dendritic cells (0.03% ± 0.007), monocytes/macrophages subsets (0.42 ± 0.14%), 129 neutrophils (1.80% ± 0.53) and alveolar macrophages (0.05% ± 0.01). Moreover, non-130 hematopoietic cells such as AT-II and endothelial cells represented $0.24\% \pm 0.05$ and $0.5\% \pm 0.15$ 131 out of the total live cell fraction, respectively (Figure 1A). All populations have been previously 132 identified in human lungs [24, 26, 27]. Moreover, the nature of AT-II cells in lung cell suspensions 133 was confirmed by staining with phosphatase alkaline (Figure 1B), which has been shown to be a 134 reliable marker of type II cell phenotype both in vitro and in vivo [28]. Next, we focus on the 135 expression of previously identified proteins involved in viral entry. Single-cell transcriptome 136 studies have shown that ACE2, one of the main host cell surface receptors for SARS-CoV-2 137 attachment and infection, is predominantly expressed by AT-II cells [8, 29]. Moreover, ACE2 138 expression wanes in distal bronchiolar and alveolar regions paralleled by SARS-CoV-2 infectivity 139 [8]. In human parenchyma lung cells, we found ACE2 expression mainly in AT-II cells (Figure 1C), 140 a finding that was confirmed by immunohistochemistry (Figure 1D). Percentage of AT-II cells 141 expressing ACE2 was rather small and varied between individuals (6.29% ± 1.00) (Figure 1C), as 142 previously described [7]. We also studied the expression of CD147 on lung cells, which has been reported as a novel route of SARS-CoV-2 infection in vitro and in vivo models [30]. CD147 was 143 144 ubiquitously expressed in several hematopoietic and non-hematopoietic cells (Figure 1C). 145 Importantly, 92.3% ± 1.14 of AT-II cells expressed CD147 (Figure 1C). Similarly, and in agreement 146 with other studies [31], TMPRSS2 protease expression was identified in AT-II cells (21.33% \pm 147 7.52) (Figure 1C). Overall, we found that human lung suspensions preserved critical cell populations and the expression of factors required for SARS-CoV-2 infection. 148

149 Susceptibility of HLT cells to SARS-CoV-2 viral entry

150 Next, we assessed if HLT cells were susceptible to viral infection. We generated pseudotyped 151 vesicular stomatitis virus (VSV) viral particles bearing the S protein of SARS-CoV-2 and expressing 152 either luciferase (VSV* Δ G (Luc)-S) or GFP (VSV* Δ G (GFP)-S) reporter genes upon cell entry. As a control, we used the VSV-G virus, which has very broad cell tropism. As expected, VeroE6 cells 153 154 were highly susceptible to SARS-CoV-2 entry, as demonstrated for VSV* ΔG (GFP)-S and VSV- ΔG 155 (Luc)-S (Figure 2A). Anti-ACE2 antibody blocked more than 90% of VSV* Δ G (Luc)-S, but was 156 inactive for VSV-G (Luc) infection (Figure 2B). This observation has been widely reported before 157 [10, 32, 33], and identifies ACE2 as the main cell receptor required for viral entry in VeroE6. 158 Importantly for viral pathogenesis, it has been postulated that SARS-CoV-2 S protein might 159 downregulate ACE2 expression, as previously observed for SARS-CoV [34]. We consistently observed a significant strong reduction in ACE2 expression after viral entry (Figure 2C). 160

We then evaluated the susceptibility of HLT cells to viral entry, using the same viral 161 162 constructs. HLT cells were readily infected with pseudotyped S particles (VSV* ΔG (Luc)-S and VSV* ΔG (GFP)-S), with the natural donor variation representative of primary samples (Figure 163 164 2D). As expected [8], lung cells compatible with an AT-II phenotype were identified as the main 165 cell targets in steady conditions (Figure 2E). Blockade of ACE2 resulted in a donor-dependent 166 reduction of viral infectivity, ranging from 50 to 100% (Figure 2F). Camostat, a TMPRSS2 inhibitor, significantly inhibited viral entry in all HLT assays, although the entry process was not 167 168 always completely abrogated (Figure 2F), suggesting that AT-II cells may become infected 169 through the use of alternative factors [35]. Similarly, the presence of an anti-CD147 antibody 170 inhibited SARS-CoV-2 entry in AT-II cells (Figure 2F). Collectively, these data indicate that HLT 171 cells are highly susceptible to SARS-CoV-2 viral entry, and that ACE2, CD147 and TMPRSS2 are important proteins for viral entry in human lung cells. Overall, these results support the value of 172 173 the HLT model to successfully study SARS-CoV-2 viral entry, and related mechanisms, in a more 174 physiological system.

175 Antiviral assays in the HLT model

To validate the HLT model as a platform for the screening of antiviral candidates, we assayed potential antiviral compounds, most of them previously identified by computational methods with predicted ability to inhibit SARS-CoV-2 cell entry due to their interaction with S protein or with the interface S-ACE2 [36]. A detailed description of the 39 selected drugs is available in **Table S1**. HLT cells were exposed to VSV* Δ G (Luc)-S virus in the presence of 1/5 serial dilution of the different tested compounds. 20h post-exposure, antiviral activity and cell viability were 182 measured by luminescence. Results in HLT cells were systematically compared with antiviral 183 testing performed in the cell line VeroE6. Among 39 drugs that were evaluated in our study, 16 184 (41%) showed some antiviral activity against SARS-CoV-2 with EC_{50} values ranging from 0.5µM 185 to 66µM (Table S2). We observed that 23% of drugs had concordant results between both 186 models (Figure 3). Cepharanthine, a naturally occurring alkaloid reported to have potent anti-187 inflammatory and antiviral properties, was one of the most potent antivirals identified in both 188 systems, with EC₅₀ of 0.4µM and 6.1µM in VeroE6 and HLT cells, respectively (Figure 3A and B). 189 Of note, we observed cell toxicity at the highest concentrations ($CC_{50 \text{ VeroE6}}$ = 22.3 μ M; $CC_{50 \text{ HLT}}$ = 190 13.8µM), which translated in a satisfactory selectivity index (SI) in VeroE6 cells, but close to the 191 standard threshold of 2 in HLT cells (SI VeroE6 = 55.7; SI HLT = 2.2) [37]. The anti-SARS-CoV-2 activity 192 of hydroxychloroquine, a compound known to interfere with endosomal acidification necessary 193 for the proteolytic activity of cathepsins, has been extensively reported [38, 39]. In our study, 194 we observed that hydroxychloroquine was equally effective at inhibiting viral entry in VeroE6 195 and HLT cells (EC_{50 VeroE6}= 1.58μ M; EC_{50 HLT}= 9.26μ M) (**Figure 3A, B**), with no apparent cytotoxicity 196 (Figure 3C). Ergoloid, an approved drug used for dementia, and recently identified as a potential 197 inhibitor of SARS-CoV-2 main protease [40], induced a ~90% viral entry inhibition in HLT cells at 198 non-toxic concentrations (Figure 3A-C). Indeed, SI for this compound was higher in the HLT 199 model than in VeroE6 cells ($SI_{VeroE6} = 3.9$; $SI_{HLT} = 11.38$). Similarly, ivermectin, a broad-spectrum 200 anti-parasitic compound, showed very similar antiviral potency in both models, however SI 201 greatly differed ($SI_{VeroE6} = 1.4$; $SI_{HLT} = 8$). Additionally, we also calculated the *Coefficient of* 202 Variation (CV) of the antiviral assays as a measure of relative variation in 50% Effective 203 Concentration (EC_{50}) values. We show that the CV varied from 0.9 to 15.36% in HLT cells (Figure 204 **3D**). The low CV obtained highlights the suitability of the HLT model for the identification of 205 antivirals.

206 We also detected discordant antiviral results between both models (Figure 4). Indeed, 5 207 drugs inhibited SARS-CoV-2 entry in HLT cells without affecting cell viability, but no effect was 208 observed in VeroE6 (Figure 4A-C). As expected, camostat, a TMPRSS2 inhibitor [41], was not 209 active in VeroE6 cells due to lack of TMPRSS2 expression in this cell line. However, camostat was 210 highly active in HLT cells ($EC_{50}=2.7\mu$ M). Indeed, a clinical trial testing its potential to prevent 211 SARS-CoV-2 transmission is ongoing (NCT04625114). Further, sulindac, a nonsteroidal anti-212 inflammatory drug, and valaciclovir, an antiviral drug, presented some inhibitory potential at 213 100 μM only in HLT cells. Interestingly, phenformin, an antidiabetic drug and an mTOR inhibitor, 214 has been postulated as an inhaled drug candidate against influenza and coronavirus infections 215 [42]. Phenformin reduced the incidence of influenza infection in diabetic patients during the

216 1971 outbreak [42]. Here, we observed that phenformin significantly reduced viral entry starting 217 at 4μ M only in HLT cells, supporting previous recommendations as inhaled treatment. Finally, 218 eriodictyol, a flavonoid used as a medicinal plant [43], demonstrated certain activity at 20-219 100µM. In contrast, luteolin induced potent viral entry suppression only in VeroE6 cells at high 220 concentrations (Figure 4A-C). Overall, these results indicate that the HLT is a reproducible and 221 highly relevant model for antiviral testing in a physiological system that recapitulates main 222 antiviral activities observed in cell models, and offers the identification of new compounds 223 missed by conventional systems.

Impact of inflammation and anti-inflammatory drugs on ACE2 expression and SARS-CoV-2 viral entry

226 Since SARS-CoV-2 viral infection rapidly induces an inflammatory response, we wondered if 227 certain components of this response could modulate ACE2 expression, potentially allowing 228 increased viral binding of SARS-CoV-2 and thus, enhancing infection. Further, ACE2 has been 229 previously identified as an ISG or a component of the IFN-signaling pathway [11, 44], and a 230 recent investigation showed that cultured human primary basal epithelial cells treated with IFN-231 α^2 and IFN-y led to upregulation of ACE2 [11]. Moreover, IL-1 β and IFN- β upregulated ACE2 in 232 large airway epithelial cell cultures [8]. Thus, considering that type I interferons represent a first 233 line of defence against viral infections and that several cytokines are rapidly induced and 234 associated with disease severity in COVID-19 patients [45], we tested the effects of different 235 molecules on ACE2 expression in our model. In initial experiments, we tested three different 236 doses of a wider range of molecules (including tumor necrosis factor (TNF), IL-6 and IFN-y), which 237 were used to select doses and compounds of interest. Finally, the effect of IFN- $\alpha 2$, IFN- $\beta 1$, IL-238 1β, IL-10 and GM-CSF on ACE2 expression was evaluated in the HLT model. Cells were then 239 treated with selected immune stimuli and cultured for 20h, when the expression of ACE2 in AT-240 II cells was evaluated by flow cytometry. The only significant change we observed was for IL-1 β 241 stimulation, which decreased the fraction of AT-II cells expressing ACE2 (Figure 5A). No other 242 significant changes were observed. Overall, we show that relevant inflammatory stimuli have a 243 limited impact on ACE2 expression in AT-II cells, while the effect and impact of IL-1 β on viral 244 infection should be further explored.

It is currently not well documented if anti-inflammatory drugs could modulate ACE2 expression, and consequently, might impact susceptibility to SARS-CoV-2 infection [46]. Several glucocorticoids have shown to impart activating effects on ACE2 expression in cell lines; cortisol showed the strongest effect on ACE2 activation, followed by prednisolone, dexamethasone, and 249 methylprednisolone [15]. Moreover, NSAIDs, compounds that inhibit cyclooxygenase-1 and 2 250 mediating the production of prostaglandins, which play a role in inflammatory responses, have 251 been linked to ACE2 upregulation [15]. Here, we took advantage of our HLT model to study the 252 effect of several anti-inflammatory drugs on both ACE2 expression and SARS-CoV-2 viral entry. 253 1/5 dilutions of ibuprofen, cortisol, dexamethasone and prednisone were added to HLT cells for 254 20h. Overall, no effect on ACE2 expression was observed after the addition of these anti-255 inflammatory drugs (Figure 5B). Consequently, the antiviral assay showed no major impact of 256 anti-inflammatory compounds on viral entry; however, high concentrations of prednisone and 257 dexamethasone showed a partial reduction of viral entry in HLT cells, without any apparent 258 impact on VeroE6 (Figure 5C). Thus, we show that selected anti-inflammatory drugs have limited 259 impact on ACE2 expression within AT-II cells present in the HLT model, as well as in SARS-CoV-2 260 viral entry.

261 Anti-inflammatory properties of selected compounds

262 Last, we were interested in modelling the anti-inflammatory properties of several drugs in 263 our HLT model. Based on their antiviral potency in HLT cells, we selected cepharanthine, 264 ergoloid, camostat, ivermectin, hydroxychloroquine and ciclesonide for further evaluation. Of 265 note, some of these drugs have been previously identified as immunomodulators with anti-266 inflammatory effects (Table S1). However, their direct impact on inflammatory molecules 267 directly secreted by human lung cells has not been evaluated. HLT cells were stimulated with 268 lipopolysaccharides (LPS) and IFN-y in the presence of these antivirals and, 20h after, the 269 expression of IL-6 and CXCL10, a potent pro-inflammatory cytokine and chemokine respectively, 270 was intracellularly measured by flow cytometry. As shown in Figure 6A, two major 271 subpopulations of myeloid cells contributed to the upregulation of CXCL10 and IL-6 expression 272 upon stimulation. Myeloid CD11b⁺CD14⁺ were the cells with a greater response, showing 50% 273 of cells expressing IL-6 and 30% expressing CXCL10 after stimulation (Figure 6B). Using this 274 model of local inflammation, we tested the capacity of the selected compounds to modify this 275 response. We observed that camostat had the most potent effect, which significantly reduced 276 the expression of CXCL10 in CD11b⁺CD14⁻ and of IL-6 in CD11b⁺CD14⁺ myeloid subsets (Figure 277 **6B**). Ergoloid, which has not been linked to modulation of inflammation before, significantly 278 reduced the expression of cytokines in CD11b⁺ CD14⁺ myeloid cells, and cepharantine reduced 279 IL-6 production from this subset. Finally, ciclesonide induced CXCL10 secretion in CD11b⁺CD14⁻ 280 myeloid cells (Figure 6B). Altogether, our results validate the HLT model as a relevant method 281 for the identification of anti-inflammatory compounds impacting specific pro-inflammatory cell 282 populations from the lung parenchyma.

283 Discussion

284 The emergency created by the rapid spread of SARS-CoV-2 infection worldwide required a 285 quick response from physicians treating these patients, who adapted to the rapid knowledge 286 being generated by both clinical practice and basic research. However, up to date, no specific 287 drugs against SARS-CoV-2 have been approved for clinical use. In this sense, the choice of the 288 cell and animal models used to test the efficacy of antivirals will impact its rapid translation into 289 the clinics. Here, we have developed a novel human lung tissue (HLT) model that can be safely 290 performed in a BSL2 facility, which allows i) the identification of cell targets and expression of 291 viral entry factors, ii) the impact of inflammation on host-pathogen interactions and iii) a rapid 292 medium-high throughput drug screening of SARS-CoV-2 entry inhibitors and local anti-293 inflammatory candidates.

294 While cell lines have been traditionally used for the screening of potential antiviral 295 compounds due to their reproducibility, as well as being quick and user-friendly assays, they lack 296 physiological relevance. Similarly, entry receptors and viral factors have been identified using 297 immortalized cell lines [10, 47], and cell targets for SARS-CoV-2 in tissues have been mainly 298 determined by analyzing the expression of viral entry factors in RNA-seq datasets [48] or using 299 replication-competent SARS-CoV-2 isolates in BSL3 facilities [49]. Importantly, these studies 300 have identified AT-II cells as main viral targets for SARS-CoV-2 infection in the lungs, and the 301 molecules ACE2, CD147 and TMPRSS2 as the main factors for viral entry [10, 30, 50]. However, 302 the development of more refined and translational ex vivo models of SARS-CoV-2 entry will not 303 only have implications for understanding viral pathogenesis, but also will be useful for the 304 characterization of cell targets under specific conditions and the identification of potential 305 antivirals blocking infection of primary cells. In our HLT model, the maintenance of cell type 306 complexity in their in vivo proportions may represent a significant advantage over previous 307 models [17, 19, 51]. Using pseudotyped viral particles expressing SARS-CoV-2 spike, we first 308 corroborated that AT-II cells are the primary cell target in lung tissue in steady conditions. This 309 agrees with several studies using different approximations [11, 52, 53] and validates our primary 310 model for viral tropism identification.

Moreover, we showed that the HLT model can be successfully used for drug screening purposes. We tested 39 drugs and compared the results with antiviral testing in VeroE6 cells. Not surprisingly, we showed discordant results between both models. Indeed, we found that 37.5% of the tested compounds had discordant results between HLT and VeroE6 cells; 31.25% of drugs showed some antiviral effect in HLT but no activity was detected in VeroE6, and 6.2% 316 showed only antiviral effects in VeroE6 cells. Among other reasons, the differential expression 317 of several key proteins needed for viral entry, might explain current discrepancies between 318 models. Importantly, using the HLT model, we identified several compounds with antiviral 319 activity; cepharanthine showed an EC_{50} of 6.1µM and concordantly, it was recently identified in 320 a high throughput screening as one of the most potent drugs against SARS-CoV-2 [54], likewise 321 several other studies have pointed towards this drug as a potent entry and post-entry SARS-CoV-322 2 inhibitor [55]. Instead, for hydroxychloroquine, an early report suggested no antiviral activity 323 in human lung cells due to different expression of the required proteases for viral entry [56]. In 324 our study, however, we observed that this drug was equally effective at inhibiting viral entry in 325 VeroE6 and HLT cells. Nevertheless, clinical trials failed to show effectiveness of this drug as a 326 treatment for COVID-19 [57-59]. Recently, a strong dependency of SARS-CoV-2 on TMPRSS2 for 327 viral entry, rather than on cathepsin L, was identified as a possible mechanistic explanation for 328 its failure in vivo [60]. Similarly, we identified ivermectin as an effective antiviral in HLT cells. Of 329 note, ivermectin received limited attention as a potential drug to be repurposed against COVID-330 19 based on its limited ability to reach lung tissue in vivo [61]. Further, a clinical trial failed to 331 show a reduction in the proportion of PCR-positive patients seven days after ivermectin 332 treatment [62].

333 Importantly, the HLT model also provides a platform for testing anti-inflammatory drugs and 334 the modulation of viral entry factors with drug candidates and immunomodulatory stimuli. We 335 showed that IL-1 β was able to reduce ACE2 expression in AT-II cells, in contrast to other 336 cytokines induced during SARS-CoV-2 infection like IFN-α2, IFN-β1, IL-10 and GM-CSF, which did 337 not impact ACE2 protein production. In primary epithelial cells derived from healthy nasal 338 mucosa, Ziegler et al. [11] showed a significant induction of ACE2 transcripts after IFN- α 2 and 339 IFN-y stimulation, as well as and in a human bronchial cell line treated with either type I or type 340 II IFN. Moreover, the authors showed that influenza A virus infection increased ACE2 expression 341 in lung resections [11], strongly suggesting that ACE2 was an ISG. However, following studies 342 showed that ACE2 transcription and protein production was not responsive to IFN. Instead, they 343 described a new RNA isoform, MIRb-ACE2, that was highly responsive to IFN stimulation, but 344 importantly, encoded a truncated and unstable protein product [63, 64]. These results highlight 345 the need to validate scRNA-seq data with orthogonal approaches, such as the confirmation of 346 protein expression levels in relevant systems. In the HLT model, we quantified ACE2 protein 347 expression and importantly, focused our analysis on AT-II cells, the main SARS-CoV-2 targets in 348 lung parenchyma. Also, in agreement with our results, a primary human bronchial epithelial cell 349 model, type I (β), II (γ), or III (λ 1) IFNs did not induced ACE2 expression [65]. Moreover, a study

performed by Lang et al [66], showed that IFN- γ and IL-4 downregulate the SARS-CoV receptor ACE2 in VeroE6 cells, and similarly, stimulation of A549 cells with IFN- α , IFN- γ , and IFN- α +IFN- γ did not identify ACE2 as an ISG [67].

353 A feasible explanation for the increase of ACE2 protein production upon IL-1 β treatment is 354 that IL-1β activates disintegrin and metalloproteinase domain-containing protein 17 (ADAM17) 355 [68], which mediates the shedding of ACE2 [69]. Although this effect would seem positive to 356 reduce SARS-CoV-2 infection, ACE2 is a lung-protective factor, as it converts Angiotensin (Ang) 357 II to Ang-(1–7); while Ang II promotes harmful effects in the lung, e. g. fibrosis, vasoconstriction, 358 inflammation, endothelial dysfunction, edema, and neutrophil accumulation[70], Ang-(1-7) has 359 counter-regulatory effects protective of lung injury. Moreover, Ang-(1–7) plays an essential role 360 in hemostasis, as it favors anti-thrombotic activity in platelets [71]. In any case, treatment of 361 COVID-19 patients with respiratory insufficiency and hyper inflammation with IL-1 inhibitors was 362 associated with a significant reduction of mortality [72], indicating that at least during severe 363 COVID-19 the overall effect of IL-1 β is detrimental. While the reduction of ACE2 expression in 364 AT-II cells by IL-1 β may be of interest, it needs to be determined if in combination with other 365 cytokines rapidly induced during viral respiratory infection [73], this effect would remain.

366 Further, glucocorticoids and NSAIDS have been linked to ACE2 upregulation previously [15]. 367 In contrast, we did not observe any significant impact of ibuprofen, cortisol, dexamethasone and 368 prednisone on ACE2 protein expression. These results are concordant with a recent report 369 showing that suppression of ciclooxigenase (COX)-2 by two commonly used NSAIDs, ibuprofen 370 and meloxicam, had no effect on ACE2 expression, viral entry, or viral replication in a mouse 371 model of SARS-CoV-2 infection [74]. Moreover, dexamethasone incompletely reduced viral 372 entry. This observation partially agrees with a study using lung cells previously treated with 373 dexamethasone, which showed significant suppression of SARS-CoV-2 viral growth [24].

374 In addition, we used the model for testing local inflammation and potential anti-375 inflammatory drugs. Several resident and recruited myeloid subsets may contribute to the rapid 376 cytokine storm detected in COVID-19 patients [75-77]. Thus, the identification of antiviral drugs 377 that can also limit the extent of these initial pro-inflammatory events may offer added value to 378 the overall therapeutic effect of a given drug. In this sense, we observed that camostat 379 significantly reduced the expression of proinflammatory molecules IL-6 and CXCL10 in several 380 myeloid CD11b⁺ subsets. Concordantly, in a previous study using primary cultures of human 381 tracheal epithelial cells infected with H1N1 virus, camostat also reduced the concentrations of 382 the cytokines IL-6 and TNF in cell supernatants [78], suggesting a potent anti-inflammatory potential. In contrast, ivermectin did not affect the expression of cytokines in our model.
Differing from previous results, ivermectin was shown to have anti-inflammatory effects in mice
and *in vitro* using murine macrophages; ivermectin reduced the production of TNF, IL-1 and IL6, and suppressed LPS-induced NF-κB translocation[79]. Of note, our HLT model of inflammation
is optimized up to detect changes in the intracellular expression of cytokines by local myeloid
cells, and thus, how these intracellular changes reflect total cytokine production in supernatant
needs further evaluation.

390 Finally, it is also important to note the potential limitations of the model, including the limited 391 availability of human lung samples, inter-patient variation (age, smoking, etc.), the effects on 392 lung biology of the medical condition instigating surgery, and the location of the sample 393 resection which may affect the proportion of cell subsets such as AT-II. However, this variability 394 is what shapes the HLT into a highly physiological and relevant model in comparison to current 395 methods based on immortalized cell cultures. Besides the interest of the model proposed here, 396 our results highlight drugs with antiviral activity in HLT cells together with immunomodulatory 397 properties, which could increase the benefit of this treatment during COVID-19 disease 398 progression. For instance, camostat, cepharantine and ergoloid were three of the most potent 399 drugs inhibiting SARS-CoV-2 entry, and remarkably, also exerted a significant anti-inflammatory 400 effect on myeloid cells. Clinical trials with camostat, currently ongoing, ergoloid and 401 cepharatine, will shed light on their use as both antivirals and anti-inflammatory compounds.

402 Materials and methods

403 Cells and virus

404 VeroE6, isolated from kidney epithelial cells of an African green monkey, were grown in 405 DMEM medium supplemented with 10% fetal bovine serum (FBS; Gibco) 100 U/ml penicillin, 406 and 100 μ g/ml streptomycin (Capricorn Scientific) (D10) and maintained at 37°C in a 5% CO₂ 407 incubator.

408 The spike of the SARS-CoV-2 virus was generated (GeneArt Gene Synthesis, ThermoFisher 409 Scientific) from the codon-optimized sequence obtained by Ou et al.[35] and inserted into 410 pcDNA3.1D/V5-His-TOPO (pcDNA3.1-S-CoV2Δ19-G614). This plasmid presents the mutation 411 D614G and a deletion in the last 19 amino acids from the original spike. Pseudotyped viral stocks 412 of VSV* Δ G(Luc)-S were generated following the protocol described by Whitt [80] with some 413 modifications. Briefly, 293T cells were transfected with 3µg of the plasmid encoding the SARS-414 CoV-2 spike. Next day, cells were infected with a VSV-G-Luc virus (MOI=1) (generated from a 415 lentiviral backbone plasmid that uses a VSV promoter to express luciferase) for 2h and gently 416 washed with PBS. Cells were incubated overnight in D10 supplemented with 10% of I1 417 hybridoma (anti-VSV-G) supernatant (ATCC CRL-2700) to neutralize contaminating 418 VSV* Δ G(Luc)-G particles. Next day, the resulting viral particles were collected and titrated in 419 VeroE6 cells by enzyme luminescence assay (Britelite plus kit; PerkinElmer), as described 420 previously [81].

421 Lung tissue

422 Lung tissues were obtained from patients without previous COVID-19 history and a recent 423 negative PCR test for SARS-CoV-2 infection undergoing thoracic surgical resection at the 424 Thoracic Surgery Service of the Vall d'Hebron University Hospital. Study protocol was approved 425 by the Ethical Committee (Institutional Review Board number PR(AG)212/2020). Non-neoplastic 426 tissue areas were collected in antibiotic-containing RPMI 1640 and immediately dissected into 427 approximately 8-mm³ blocks. These blocks were first enzymatically digested with 5 mg/ml 428 collagenase IV (Gibco) and 100 μg/ml of DNase I (Roche) for 30 min at 37^oC and 400 rpm and, 429 then, mechanically digested with a pestle. The resulting cellular suspension was filtered through 430 a 70µm-pore size cell strainer (Labclinics) and washed twice with PBS. Pellet recovered after 431 centrifugation was resuspended in fresh medium (RPMI 1640 supplemented with 5% FBS, 100 432 U/ml penicillin, and 100 μ g/ml streptomycin) and DNase I to dissolve cell aggregates, and the 433 resulting cell suspension was then filtered through a 40µm-pore size cell strainer (Labclinics).

Cell number and viability were assessed with LUNA[™] Automated Cell Counter (Logos 434 435 Biosystems). For cell phenotyping the following antibodies were used: anti-CD31 (PerCP-Cy5.5, 436 BioLegend), anti-CD11b (FITC, BioLegend), anti-CD11c (Pe-Cy7, BD Biosciences), anti-E-cadherin 437 (Pe-CF594, BD Biosciences), primary goat anti-ACE2 (R&D systems), anti-CD14 (APC-H7, BD 438 Biosciences), anti-CD45 (AF700, BioLegend), anti-EpCAM (APC, BioLegend), anti-CD3 (BV650, BD Biosciences), anti-CD15 (BV605, BD Biosciences) and anti-HLA-DR (BV421, BioLegend). For ACE2 439 440 detection, after surface staining, cells were stained with secondary donkey anti-goat IgG (PE, 441 R&D Systems) for 30 min at 4 °C. Cell viability was determined using an AQUA viability dye for 442 flow cytometry (LIVE/DEAD fixable AQUA, Invitrogen). In some experiments, instead of CD11b 443 or CD15, we used a primary rabbit anti-TMPRSS2 or anti-CD147 (BV605, BD Biosciences), 444 respectively. For TMPRSS2 detection, after ACE2 staining with the appropriate secondary 445 antibody, cells were washed twice with PBS 1% NMS (normal mouse serum) and then stained 446 with a secondary goat anti-rabbit IgG (AF488, Thermofisher) for 30 min at 4°C. After fixation 447 with PBS 2% PFA, cells were acquired in an LSR Fortessa (BD Biosciences), and data were 448 analyzed using the FlowJo v10.6.1 software (TreeStar).

449 Cytospin and alkaline phosphatase staining

450 Cytospin preparations were obtained from freshly isolated human lung cells at an 451 approximate density of 150,000 cells/slide, and air-dried during 15 min. Cells were stained with 452 alkaline phosphatase, as an enzyme marking epithelial type II cells, following manufacturer's 453 instructions (Alkaline phosphatase Kit, Sigma). The intensity of pink stain reflects the amount of 454 alkaline phosphatase in positive cells.

455 ACE2 immunohistochemical staining in human lung tissue sections

456 Human lungs were maintained in 10% formalin for 24 hours and then embedded in paraffin. 457 Paraffin-embedded lungs were cut into 4 µm sections. After removing the paraffin, endogenous 458 peroxidases were inactivated in an aqueous solution containing 3% H₂O₂ and 10% methanol and 459 antigen retrieval was performed heating the samples in citrate buffer (10mM citric acid, pH 6.0). 460 The sections were then blocked in bovine serum albumin (5%), incubated with anti-ACE2 461 antibody (R&D Systems cat. nº AF933, dilution 1:100) and with biotinylated secondary antibody 462 against goat IgGs (Vector Laboratories cat. nº BA-9500, dilution 1:250). Proteins were visualized 463 using the ABC Peroxidase Standard Staining Kit (ThermoFisher) followed by 3,3'-464 Diaminobenzidine (DAB) Enhanced Liquid Substrate System (Sigma Aldrich). Counterstaining 465 was done with hematoxylin.

466 Antiviral screening assay

467 The complete list of compounds tested in this study, including information about its clinical 468 use, product reference and vendors is shown in **Table S1**. Duplicates of five-fold serial dilutions 469 of 39 antiviral compounds were tested in both VeroE6 cell line and in human lung tissue (HLT) 470 cells using at least 2 different donors. For VeroE6, five-fold serial dilutions of the compounds, 471 ranging from 100μ M to 0,25nM, were prepared in D10 in a 96-well flat-bottom plates. VeroE6 472 cells were added at a density of 30.000 cells/well and incubated with the drug for at least 1 h 473 before infection. Subsequently, cells were infected with 1,500 TCID₅₀ of VSV* Δ G(Luc)-S virus. In 474 parallel, drug cytotoxicity was monitored by luminescence. To evaluate the antiviral activity of 475 drugs in HLT cells, five-fold serial dilutions of the compounds, ranging from 100µM to 0.8µM or 476 6.4nM, were prepared in R10 in a 96-well conic bottom plates. HLT cells were added at a density 477 of 300,000 cells/well and incubated with the compound for at least 1h before infection. Then, 478 MOI 0,1 of VSV* $\Delta G(Luc)$ -S virus were added to wells, and plates were spinoculated at 1,200g 479 and 37°C for 2h. After infection, fresh medium was added to the wells and cell suspensions were 480 transferred into a 96-well round-bottom plate. Cells were then cultured overnight at 37°C in a 481 5% CO₂ incubator. Each plate contained the following controls: no cells (background control), 482 cells treated with medium (mock infection) and cells infected but untreated (infection control). 483 After 20h, cells were incubated with Britelite plus reagent (Britelite plus kit; PerkinElmer) and 484 then transferred to an opaque black plate. Luminescence was immediately recorded by a 485 luminescence plate reader (LUMIstar Omega). To evaluate cytotoxicity, we used the CellTiter-Glo[®] Luminescent kit (Promega), following the manufacturer's instructions. Data was 486 487 normalized to the mock-infected control, after which EC_{50} and CC_{50} values were calculated using 488 Graph-Pad Prism 7.

489 Modulation of ACE2 expression by anti-inflammatory drugs and immune stimuli

490 VeroE6 and lung cells were incubated with five-fold serial dilutions of selected antiinflammatory compounds (ranging from 100µM to 0.8µM) for 20h. Tested drugs included 491 492 cortisol, ibuprofen, prednisone and dexamethasone. Lung cells were also incubated with the 493 following cytokines: GM-CSF (100 ng/ml, Immunotools), IL-1 β (10 ng/ml, Immunotools), IL-10 494 (100 ng/ml, Immunotools), IFN- β (100 U/ml, Immunotools), or IFN- α 2 (100 U/ml, Sigma Aldrich). For determination of ACE2 expression, the following surface staining antibodies were used: 495 496 primary goat anti-ACE2 (R&D Systems), anti-CD45 (AF700, BioLegend), anti-EpCAM (APC, 497 BioLegend), and anti-HLA-DR (BV421, BioLegend). For ACE2 detection, cells were then stained 498 with secondary donkey anti-goat IgG (PE, R&D Systems) for 30 min at 4 °C. A Fluorescent Minus

One control (FMO) without primary anti-ACE2 antibody was used as a control. Cell viability was
determined using an AQUA viability dye for flow cytometry (LIVE/DEAD fixable AQUA,
Invitrogen). After fixation with PBS 2% PFA, cells were acquired in an LSR Fortessa (BD
Biosciences) and analyzed using the FlowJo v10.6.1 software (TreeStar).

503 Immunomodulatory capacity of selected drugs

504 HLT cells were cultured in a round-bottom 96-well plate containing 20 µM of cepharanthine, 505 ergoloid mesylate, ciclesonide, hydroxychloroquine, ivermectin, or camostat mesylate alone or 506 in combination with the stimuli LPS (50 ng/ml) and IFN-y (100 ng/ml). For each patient, a 507 negative control, cells treated with only medium, and a positive control, cells incubated in the 508 presence of LPS and IFN-y, were included. Immediately, brefeldin A (BD Biosciences) and monensin (BD Biosciences) were added to cells and cultured overnight at 37 °C in 5% CO₂. Next 509 510 day, cellular suspensions were stained with the following antibodies: anti-CD11b (FITC, 511 BioLegend), anti-CD69 (PE-CF594, BD Biosciences), anti-CD14 (APC-H7, BD Biosciences), anti-512 EpCAM (APC, BioLegend), anti-CD3 (BV650, BD Biosciences), anti-CD45 (BV605, BioLegend), and 513 anti-HLA-DR (BV421, BioLegend). Cells were subsequently fixed and permeabilized using the 514 Cytofix/Cytoperm[™] kit (BD Biosciences) and intracellularly stained with anti-IL-6 (PE-Cy7, 515 BioLegend), and anti-CXCL10 (PE, BioLegend). Cell viability was determined using an AQUA 516 viability dye for flow cytometry (LIVE/DEAD fixable AQUA, Invitrogen). After fixation with PBS 2% PFA, cells were acquired in an LSR Fortessa (BD Biosciences), and data were analyzed using 517 518 the FlowJo v10.6.1 software (TreeStar).

519 Statistical analyses

520 Statistical analyses were performed with Prism software, version 6.0 (GraphPad). A P value 521 <0.05 was considered significant.

522 Author contributions

- 523 Conceptualization, MJ.B. and M.G.; Sample Collection, J.R.; Methodology J.G-E, D.P, M.S, N.
- 524 M, A.V, MJ.S, J.G-P, J.A, A.S.M and V.F; Formal Analysis, J.G-E., D.P, M.S, M.G and MJ.B; Writing-
- 525 Original Draft J.G-E and MJ.B; Writing- Review & Editing, J.G-E, M.G. and MJ.B; Funding
- 526 Acquisition, M.G and MJ.B.; all authors revised the manuscript; Supervision, M.G and MJ.B.
- 527 Acknowledgments

528 This work was primarily supported by a grant from the Health Department of the 529 Government of Catalonia (DGRIS 1 5). This work was additionally supported in part by the 530 Spanish Health Institute Carlos III (ISCIII, PI17/01470), the Spanish Secretariat of Science and 531 Innovation and FEDER funds (grant RTI2018-101082-B-I00 [MINECO/FEDER]), the Spanish AIDS 532 network Red Temática Cooperativa de Investigación en SIDA (RD16/0025/0007), the European 533 Regional Development Fund (ERDF), the Fundació La Marató TV3 (grants 201805-10FMTV3 and 534 201814-10FMTV3), the Gilead fellowships GLD19/00084 and GLD18/00008 and the Becas Taller 535 Argal 2020. M.J.B is supported by the Miguel Servet program funded by the Spanish Health 536 Institute Carlos III (CP17/00179). N.M. is supported by a Ph.D. fellowship from the Vall d'Hebron 537 Institut de Recerca (VHIR). The funders had no role in study design, data collection and analysis, 538 the decision to publish, or preparation of the manuscript.

539 References

- 5401.Beigel, J.H., et al., Remdesivir for the Treatment of Covid-19 Final Report. N Engl J Med,5412020. 383(19): p. 1813-1826.
- Consortium, W.H.O.S.T., et al., *Repurposed Antiviral Drugs for Covid-19 Interim WHO* Solidarity Trial Results. N Engl J Med, 2021. **384**(6): p. 497-511.
- 5443.White, K.M., et al., Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by545targeting the host protein eEF1A. Science, 2021. **371**(6532): p. 926-931.
- Group, R.C., et al., *Dexamethasone in Hospitalized Patients with Covid-19.* N Engl J Med,
 2021. 384(8): p. 693-704.
- 548 5. Takayama, K., *In Vitro and Animal Models for SARS-CoV-2 research*. Trends Pharmacol
 549 Sci, 2020. **41**(8): p. 513-517.
- Mossel, E.C., et al., *Exogenous ACE2 expression allows refractory cell lines to support severe acute respiratory syndrome coronavirus replication.* J Virol, 2005. **79**(6): p. 384650.
- 5537.Ortiz, M.E., et al., Heterogeneous expression of the SARS-Coronavirus-2 receptor ACE2 in554the human respiratory tract. EBioMedicine, 2020. 60: p. 102976.
- 5558.Hou, Y.J., et al., SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in556the Respiratory Tract. Cell, 2020. 182(2): p. 429-446 e14.
- 557 9. Koch, J., et al., *Host Cell Proteases Drive Early or Late SARS-CoV-2 Penetration*. bioRxiv,
 558 2020.
- 55910.Hoffmann, M., et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is560Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020. 181(2): p. 271-280 e8.
- 561 11. Ziegler, C.G.K., et al., SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in
 562 Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell,
 563 2020. 181(5): p. 1016-1035 e19.
- 12. Qiao, W., et al., *Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats.* Cardiology, 2015. **131**(2): p. 97-106.
- 566 13. Moore, N., et al., *Does Ibuprofen Worsen COVID-19?* Drug Saf, 2020. **43**(7): p. 611-614.
- 567 14. Kutti Sridharan, G., et al., COVID-19 and Avoiding Ibuprofen. How Good Is the Evidence?
 568 Am J Ther, 2020. 27(4): p. e400-e402.
- 56915.Xiang, Z., et al., Glucocorticoids improve severe or critical COVID-19 by activating ACE2570and reducing IL-6 levels. Int J Biol Sci, 2020. 16(13): p. 2382-2391.
- 57116.Ravindra, N.G., et al., Single-cell longitudinal analysis of SARS-CoV-2 infection in human572bronchial epithelial cells. bioRxiv, 2020.
- 57317.Si, L., et al., Human organs-on-chips as tools for repurposing approved drugs as potential574influenza and COVID19 therapeutics in viral pandemics. bioRxiv, 2020: p.5752020.04.13.039917.
- 57618.Blanco-Melo, D., et al., Imbalanced Host Response to SARS-CoV-2 Drives Development577of COVID-19. Cell, 2020. 181(5): p. 1036-1045 e9.
- 57819.Lamers, M.M., et al., An organoid-derived bronchioalveolar model for SARS-CoV-2579infection of human alveolar type II-like cells. EMBO J, 2021. 40(5): p. e105912.
- 58020.Kim, J., B.K. Koo, and J.A. Knoblich, Human organoids: model systems for human biology581and medicine. Nat Rev Mol Cell Biol, 2020. **21**(10): p. 571-584.
- 582 21. Chang, Y., et al., Upregulation of IL-17A/F from human lung tissue explants with cigarette
 583 smoke exposure: implications for COPD. Respir Res, 2014. 15: p. 145.
- Hackett, T.L., et al., Oxidative modification of albumin in the parenchymal lung tissue of *current smokers with chronic obstructive pulmonary disease*. Respir Res, 2010. 11: p.
 180.
- 58723.Rimington, T.L., et al., Defining the inflammatory signature of human lung explant tissue588in the presence and absence of glucocorticoid. F1000Res, 2017. 6: p. 460.

589	24.	Schaller, M.A., et al., In vitro infection of human lung tissue with SARS-CoV-
590		2: Heterogeneity in host defense and therapeutic response. bioRxiv, 2021: p.
591		2021.01.20.427541.
592	25.	Hasegawa, K., et al., Fraction of MHCII and EpCAM expression characterizes distal lung
593		epithelial cells for alveolar type 2 cell isolation. Respir Res, 2017. 18(1): p. 150.
594	26.	Singer, B.D., et al., Flow-cytometric method for simultaneous analysis of mouse lung
595		epithelial, endothelial, and hematopoietic lineage cells. Am J Physiol Lung Cell Mol
596		Physiol, 2016. 310 (9): p. L796-801.
597	27.	Baharom, F., et al., Human Lung Mononuclear Phagocytes in Health and Disease. Front
598		Immunol, 2017. 8 : p. 499.
599	28.	Katsumiti, A., et al., Immortalisation of primary human alveolar epithelial lung cells using
600		a non-viral vector to study respiratory bioreactivity in vitro. Sci Rep, 2020. 10(1): p.
601		20486.
602	29.	Qi, F., et al., Single cell RNA sequencing of 13 human tissues identify cell types and
603		receptors of human coronaviruses. Biochem Biophys Res Commun, 2020. 526(1): p. 135-
604		140.
605	30.	Wang, K., et al., CD147-spike protein is a novel route for SARS-CoV-2 infection to host
606		cells. Signal Transduct Target Ther, 2020. 5(1): p. 283.
607	31.	Qiao, Y., et al., Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2
608		and TMPRSS2. Proc Natl Acad Sci U S A, 2020.
609	32.	Condor Capcha, J.M., et al., Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral
610		Entry and Neutralization Assays: A 1-Week Protocol. Front Cardiovasc Med, 2020. 7: p.
611		618651.
612	33.	Fukushi, S., et al., Vesicular stomatitis virus pseudotyped with severe acute respiratory
613		syndrome coronavirus spike protein. J Gen Virol, 2005. 86 (Pt 8): p. 2269-2274.
614	34.	Kuba, K., et al., A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS
615		coronavirus-induced lung injury. Nat Med, 2005. 11(8): p. 875-9.
616	35.	Ou, X., et al., Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its
617		immune cross-reactivity with SARS-CoV. Nat Commun, 2020. 11(1): p. 1620.
618	36.	Smith, M.D. and J.C. Smith, Repurposing Therapeutics for COVID-19: Supercomputer-
619		Based Docking to theSARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2
620		Interface.
621	37.	Suffness, M. and J. Pezzuto, Methods in plant biochemistry: assays for bioactivity.
622		Academic Press, London, 1990: p. 71-133.
623	38.	Yao, X., et al., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of
624		Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome
625		Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases, 2020. 71(15): p. 732-739.
626	39.	Maisonnasse, P. and J. Guedj, Hydroxychloroquine use against SARS-CoV-2 infection in
627		non-human primates. 2020. 585 (7826): p. 584-587.
628	40.	Alméciga-Díaz, C.J., et al., Virtual Screening of Potential Inhibitors for SARS-CoV-2 Main
629		Protease. 2020, Preprints.org.
630	41.	Hoffmann, M., et al., Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-
631		related proteases and its metabolite GBPA exerts antiviral activity. bioRxiv, 2020.
632	42.	Lehrer, S., Inhaled biguanides and mTOR inhibition for influenza and coronavirus
633		<i>(Review)</i> . World Acad Sci J, 2020. 2 (3).
634	43.	Islam, A., et al., The pharmacological and biological roles of eriodictyol. Arch Pharm Res,
635		2020. 43 (6): p. 582-592.
636	44.	Su, S. and S. Jiang, A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by
637		enhancing expression of ACE2. Signal Transduct Target Ther, 2020. 5(1): p. 71.
638	45.	Vabret, N., et al., Immunology of COVID-19: Current State of the Science. Immunity,
639		2020. 52 (6): p. 910-941.

- 640 46. Smart, L., et al., A narrative review of the potential pharmacological influence and safety
 641 of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a
 642 dichotomy of expectation and reality. Inflammopharmacology, 2020. 28(5): p. 1141643 1152.
- 644 47. Shang, J., et al., *Cell entry mechanisms of SARS-CoV-2.* Proc Natl Acad Sci U S A, 2020.
 645 **117**(21): p. 11727-11734.
- 48. Valyaeva, A.A., et al., *Expression of SARS-CoV-2 entry factors in lung epithelial stem cells*and its potential implications for COVID-19. Sci Rep, 2020. 10(1): p. 17772.
- 64849.Kaufer, A.M., et al., Laboratory biosafety measures involving SARS-CoV-2 and the649classification as a Risk Group 3 biological agent. Pathology, 2020. 52(7): p. 790-795.
- 650 50. Walls, A.C., et al., Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
 651 Glycoprotein. Cell, 2020. 183(6): p. 1735.
- 652 51. Ogando, N.S., et al., SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics,
 653 rapid adaptation and cytopathology. J Gen Virol, 2020. 101(9): p. 925-940.
- Lukassen, S., et al., SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in
 bronchial transient secretory cells. EMBO J, 2020. 39(10): p. e105114.
- Hamming, I., et al., *Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.* J Pathol, 2004. 203(2): p.
 658 631-7.
- 54. Jeon, S., et al., *Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-*660 *Approved Drugs*. Antimicrob Agents Chemother, 2020. 64(7).
- 55. Rogosnitzky, M., P. Okediji, and I. Koman, *Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19.* Pharmacol Rep, 2020.
 72(6): p. 1509-1516.
- 66456.Hoffmann, M., et al., Chloroquine does not inhibit infection of human lung cells with665SARS-CoV-2. Nature, 2020. 585(7826): p. 588-590.
- 666 57. Omrani, A.S., et al., *Randomized double-blinded placebo-controlled trial of*667 *hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-*668 19. EClinicalMedicine, 2020. 29: p. 100645.
- 66958.Boulware, D.R., et al., A Randomized Trial of Hydroxychloroquine as Postexposure670Prophylaxis for Covid-19. N Engl J Med, 2020. 383(6): p. 517-525.
- 671 59. Mitja, O., et al., *Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A*672 *Randomized-Controlled Trial.* Clin Infect Dis, 2020.
- 60. Ou, T., et al., *Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated*by *TMPRSS2*. PLoS Pathog, 2021. **17**(1): p. e1009212.
- 675 61. Bray, M., et al., *Ivermectin and COVID-19: A report in Antiviral Research, widespread*676 *interest, an FDA warning, two letters to the editor and the authors' responses.* Antiviral
 677 Res, 2020. **178**: p. 104805.
- 678 62. Chaccour, C., et al., *The effect of early treatment with ivermectin on viral load, symptoms*679 and humoral response in patients with non-severe COVID-19: A pilot, double-blind,
 680 placebo-controlled, randomized clinical trial. EClinicalMedicine, 2021. 32: p. 100720.
- 63. Onabajo, O.O., et al., Interferons and viruses induce a novel truncated ACE2 isoform and
 682 not the full-length SARS-CoV-2 receptor. Nat Genet, 2020. 52(12): p. 1283-1293.
- 683 64. Ng, K.W., et al., *Tissue-specific and interferon-inducible expression of nonfunctional*684 *ACE2 through endogenous retroelement co-option.* Nat Genet, 2020. 52(12): p. 1294685 1302.
- 686 65. Busnadiego, I., et al., Antiviral Activity of Type I, II, and III Interferons Counterbalances
 687 ACE2 Inducibility and Restricts SARS-CoV-2. mBio, 2020. 11(5).
- 688 66. de Lang, A., A.D. Osterhaus, and B.L. Haagmans, Interferon-gamma and interleukin-4
 689 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells.
 690 Virology, 2006. 353(2): p. 474-81.

- 67. Russell, A.B., C. Trapnell, and J.D. Bloom, *Extreme heterogeneity of influenza virus*692 *infection in single cells.* Elife, 2018. **7**.
- 68. Hall, K.C. and C.P. Blobel, Interleukin-1 stimulates ADAM17 through a mechanism
 694 independent of its cytoplasmic domain or phosphorylation at threonine 735. PLoS One,
 695 2012. 7(2): p. e31600.
- 69669.Heurich, A., et al., TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis697by TMPRSS2 augments entry driven by the severe acute respiratory syndrome698coronavirus spike protein. J Virol, 2014. 88(2): p. 1293-307.
- 699 70. Domingo, P., et al., *The four horsemen of a viral Apocalypse: The pathogenesis of SARS-*700 *CoV-2 infection (COVID-19).* EBioMedicine, 2020. 58: p. 102887.
- 701 71. Fraga-Silva, R.A., et al., *The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas*702 *receptor axis: a potential target for treating thrombotic diseases.* Thromb Haemost,
 703 2012. **108**(6): p. 1089-96.
- 704 72. Cavalli, G., et al., Interleukin-1 and interleukin-6 inhibition compared with standard
 705 management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet
 706 Rheumatol, 2021. 3(4): p. e253-e261.
- 707 73. Liao, M., et al., Single-cell landscape of bronchoalveolar immune cells in patients with
 708 COVID-19. Nat Med, 2020. 26(6): p. 842-844.
- 70974.Chen, J.S., et al., Non-steroidal anti-inflammatory drugs dampen the cytokine and710antibody response to SARS-CoV-2 infection. J Virol, 2021.
- 711 75. Zhang, D., et al., COVID-19 infection induces readily detectable morphological and
 712 inflammation-related phenotypic changes in peripheral blood monocytes, the severity of
 713 which correlate with patient outcome. medRxiv, 2020.
- 71476.Fahlberg, M.D., et al., Cellular events of acute, resolving or progressive COVID-19 in715SARS-CoV-2 infected non-human primates. Nat Commun, 2020. 11(1): p. 6078.
- 716 77. Aggarwal, N.R., L.S. King, and F.R. D'Alessio, *Diverse macrophage populations mediate*717 *acute lung inflammation and resolution.* Am J Physiol Lung Cell Mol Physiol, 2014.
 718 **306**(8): p. L709-25.
- 719 78. Yamaya, M., et al., *The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells.* Pulm Pharmacol Ther, 2015. **33**: p. 66-74.
- 722 79. Zhang, X., et al., *Ivermectin inhibits LPS-induced production of inflammatory cytokines*723 *and improves LPS-induced survival in mice.* Inflamm Res, 2008. 57(11): p. 524-9.
- 80. Whitt, M.A., *Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies*on virus entry, identification of entry inhibitors, and immune responses to vaccines. J
 Virol Methods, 2010. 169(2): p. 365-74.
- Li, M., et al., Human immunodeficiency virus type 1 env clones from acute and early
 subtype B infections for standardized assessments of vaccine-elicited neutralizing
 antibodies. J Virol, 2005. **79**(16): p. 10108-25.

730 Figure legends

731 Figure 1. Phenotyping of human lung cells. (A). t-distributed Stochastic Neighbor 732 Embedding (t-SNE) representation displaying the major cell clusters present in the CD45⁺ and 733 CD45⁻ EpCam⁺ fractions of a representative human lung tissue. The vertical bars in the right panel 734 show the frequency of each subset relative to live cells. All cell subsets were identified as shown 735 in Figure S1A. mDCs, myeloid dendritic cells; AT-II, alveolar type 2. (B). Phosphatase alkaline 736 positive AT-II cells (pink staining) were detected in a cytospin obtained from human lung tissue 737 cells and observed at 10x. Lower panel shows a high magnification (40x) of the black square. 738 Scale bars are 100 μ m and 10 μ m in top and bottom panels, respectively. (C). t-distributed 739 Stochastic Neighbor Embedding (tSNE) representation for ACE2, CD147 and TMPRSS2 740 expression in CD45⁺ and CD45⁻EpCam⁺ fractions from a representative lung tissue. Right graphs 741 show the percentage of expression of each entry factor in the different cell subpopulations, 742 which were identified as in Figure 1A with some modifications for the identification of myeloid 743 cells and neutrophils (From big cells: monocytes/macrophages, CD11c⁺HLA-DR⁺CD14⁺; Alveolar 744 macrophages and mDCs, CD11c⁺ HLA-DR⁺ CD14⁻; Neutrophils, CD11c⁻ HLA-DR⁻ CD14⁻ CD3⁻). (D). 745 Images of ACE2 immunohistochemical staining in human lung tissue sections at 40x 746 magnification, counterstained with haematoxylin (top) or without (bottom). Black arrows 747 indicate staining of ACE2 in AT-II cells (upper panel). Mean±SEM is shown for all graphs.

748 Figure 2. Susceptibility of VeroE6 and the HLT model to SARS-CoV-2 viral entry. VeroE6 and 749 HLT cells were infected with two different viral constructs (GFP and Luciferase) expressing the 750 spike protein upon viral entry; VSV* $\Delta G(GFP)$ -Spike and VSV* $\Delta G(Luc)$ -Spike. (A) Representative 751 flow cytometry plots of VeroE6 cells infected with VSV* Δ G(GFP)-Spike or the background form 752 VSV*ΔG(GFP)-empty (left panel); and luciferase activity (RLUs; relative light units) at 20h post-753 infection with the pseudotyped VSV*G(Luc)-G, the VSV*ΔG(Luc)-Spike or the background form 754 VSV $^{*}\Delta G(Luc)$ -empty (right panel). (B) Percentage of viral entry after treatment with anti-ACE2 755 antibody ($10\mu g/ml$) in VeroE6 cells infected with the pseudotyped virus expressing the control 756 G protein or the spike from SARS-CoV-2. (C) A flow cytometry plot showing ACE2 expression in 757 GFP⁺ VeroE6 cells. Right graph shows mean fluorescence intensity (MFI) of ACE2 in both infected 758 and uninfected fractions, based on GFP expression. (D) Representative flow cytometry plots of 759 HLT cells infected with the viral construct expressing the spike protein (VSV* Δ G(GFP)-Spike) or 760 the background form (VSV* Δ G(GFP)-empty) (left panel); and luciferase activity (RLUs; relative 761 light units) at 20h post-infection with the VSV* Δ G(Luc)-Spike or the background form 762 VSV* Δ G(Luc)-empty (right panel). Infection was measured as the percentage of GFP or RLUs, 763 respectively. (E) Susceptible HLT cells to viral entry (identified as GFP⁺ cells) compatible with an

AT-II phenotype, determined by the co-expression of HLA-DR and EpCAM in the CD45⁻CD31⁻ fraction of live cells. (**F**) Bar plots showing the percentage of viral entry inhibition un HLT cells in the presence of anti-ACE2 antibody (15µg/ml), camostat (100µM) or anti-CD147 antibody (25µg/ml) after cell challenge with VSV* Δ G(Luc)-Spike (left graph) or VSV* Δ G(GFP)-Spike (right graph). Mean±SEM is shown for all graphs. Data in panel 2C were analyzed by a Wilcoxon matched-pairs test; *p<0,05.

770 Figure 3. Antiviral assays with concordant results between models. (A). Percentage of viral 771 entry in VeroE6 and HLT cells exposed to VSV* $\Delta G(Luc)$ -Spike in the presence of cepharanthine, 772 ergoloid, hydroxychloroquine, hypericin, licofelone, ivermectin, ciclesonide, quercitin, 773 vidarabine and celecoxib. Drugs were used at concentrations ranging from 100µM to 0.256nM. 774 in VeroE6, and to 0.8µM in lung cells. Non-linear fit model with variable response curve from at 775 least two independent experiments in replicates is shown (red lines). Cytotoxic effect on VeroE6 776 cells and HLT exposed to drug concentrations in the absence of virus is also shown (green lines). 777 (B). EC_{50} values of each drug in VeroE6 and HLT cells. (C). CC_{50} values of each drug are shown for 778 VeroE6 and for HLT cells. (D). EC_{50} 's coefficient of variation was calculated for ergoloid, 779 hydroxychloroquine and cepharanthine in the HLT model. Data includes two independent 780 experiments using different donors in replicates.

781 Figure 4. Antiviral assays with discordant results between models. (A). Percentage of viral 782 entry in VeroE6 and HLT cells exposed to VSV* $\Delta G(Luc)$ -Spike in the presence of luteolin, 783 eriodictyol, phenformin, camostat, sulindac, and valaciclovir. Drugs were used at concentrations 784 ranging from 100µM to 0.256 nM, in VeroE6, and to 0.8µM in lung cells. Non-linear fit model 785 with variable response curve from at least two independent experiments in replicates is shown 786 (red lines). Cytotoxic effect on VeroE6 cells and HLT exposed to drug concentrations in the 787 absence of virus is also shown (green lines). (**B**). EC_{50} values of each drug in VeroE6 and HLT cells. 788 (C). CC₅₀ values of each drug are shown for VeroE6 and HLT cells.

789 Figure 5. Impact of inflammation and anti-inflammatory drugs on SARS-CoV-2 viral entry 790 and ACE2 expression. Both models, HLT cells and VeroE6 cells, were incubated in the presence 791 of different anti-inflammatory drugs to evaluate the modulation of ACE2 expression by flow 792 cytometry and the antiviral effect by luminescence. (A). HLT cells were treated with different 793 stimuli for 20h and the percentage of protein expression (left) or the mean fluorescence 794 intensity (MFI, right) of ACE2 receptor was evaluated in the AT-II fraction by flow cytometry. (B) 795 Modulation of ACE2 protein expression was assessed by flow cytometry in both models, Vero 796 E6 and HLT cells, in the presence of different concentrations of each anti-inflammatory drug, 797 ranging from 100µM to 0.8µM. Percentage of ACE2 expression was quantified in AT-II cells from 798 at least six independent lung samples, and in VeroE6 cells from 2 independent experiments. (C). 799 Cytotoxic effect on Vero E6 and HLT cells exposed to VSV* $\Delta G(Luc)$ -Spike in the presence of 800 different concentrations of the anti-inflammatory drugs prednisone, cortisol, ibuprofen and 801 dexamethasone. Drugs were used at a concentration ranging from 100µM to 0.256 nM, in 802 VeroE6, and to 0.8µM in lung cells. Non-linear fit with variable response curve from at least two 803 experiments in replicates is shown (red lines). Cytotoxic effect on Vero E6 cells and HLT cells 804 exposed to different concentrations of drugs in the absence of virus is also shown (green lines). 805 Mean±SEM are shown and statistical comparisons with the control medium were performed 806 using the Wilcoxon test. *p<0.05.

807 Figure 6. Anti-inflammatory effect of compounds with antiviral activity against SARS-CoV-808 **2.** HLT cells were cultured in the presence of 20μ M of cepharanthine, ergoloid mesylate, 809 ciclesonide, hydroxychloroquine sulfate, ivermectin or camostat mesylate, alone or in 810 combination with the stimuli LPS (50 ng/ml) and IFN-y (100 ng/ml). (A) t-distributed Stochastic 811 Neighbor Embedding (t-SNE) representations displaying the major cell clusters present in live 812 CD45⁺ myeloid gate, based on FSC and SSC, of a representative human lung tissue in baseline 813 conditions and after stimulation with LPS and IFN-y. Two major subsets of myeloid cells are 814 shown (CD11b⁺ CD14⁺, in blue-green, and CD11b⁺ CD14⁻, in orange). The expression of CXCL10 815 and IL-6 among the different populations is shown in maroon and green, respectively. (B) 816 Expression of CXCL10 and IL-6 was measured in HLT cells in response to stimuli in the presence 817 of selected drugs in both myeloid subpopulations, CD11b⁺ CD14⁺ (left panel) and CD11b⁺ CD14⁻ 818 (right panel). HQ, hydroxychloroquine. Mean±SEM are represented and statistical comparisons 819 with the control medium were performed using the One sample t test. p<0.05, p<0.01.

820 Figure S1. Gating strategy for the identification of cell subpopulations in the human lung 821 tissue model. (A) General gating strategy used to identify different cell subsets in lung samples. 822 A gate based on FSC vs. SSC was followed by doublet and dead cells exclusion. From live CD45⁻ 823 cells, endothelial cells (CD31⁺, purple) and epithelial cells (EpCAM⁺, grey) were gated, and within 824 epithelial cells, AT-II cells (EpCAM⁺ and HLA-DR⁺, pink) were identified. Out of live CD45⁺ cells 825 and based on FSC vs. SSC, we identified a lymphocyte population in which we distinguished 826 between non-T lymphocytes (turquoise) and T cells (dark green) based on CD3 expression; and 827 big cells, where we identified three major subsets based on their expression of CD11b and CD11c 828 and, subsequently, CD14 and HLA-DR markers. We identified alveolar macrophages (blue), 829 monocytes (violet), myeloid dendritic cells (mDCs, fuchsia) and neutrophils (orange). (B)

Representative flow cytometry plots showing ACE2 staining and its respective fluorescenceminus one (FMO) control.

Figure S2. Optimization of lung tissue enzymatic digestion visualized by *t*-distributed Stochastic Neighbor Embedding (tSNE). (A) Representative tSNE maps showing concatenated flow cytometry standard files for three different protocols based on different digestion enzymes (collagenase, liberase or trypsin) from total live cells (upper), CD45⁺ cells (middle) and CD45⁻ cells (lower). (B) Bar plots showing cell-type composition (count) analyzed by flow cytometry for each tissue protocol.

838 Figure S3. Gating strategy for the identification of anti-inflammatory effects of selected


839 compounds. (A) General gating strategy used to evaluate the expression of inflammatory


840 molecules in lung samples. A gate based on FSC vs. SSC was followed by doublet and dead cells


841 exclusion. From live CD45⁺ cells and based on FSC vs. SSC, we identified lymphocyte population

and big cells, in which we identified two subsets based on their expression of CD11b and CD14:

843 myeloid CD11b⁺CD14⁺ cells (blue-green) and myeloid CD11b⁺CD14⁻ cells (orange) are shown.








VSV*∆G(Luc)-S VSV*∆G(GFP)-S 100-100 80 80 % infection % infection 60 60 0 00 40 40 φ 20 20 0 AntirAction AP Carrostat anti-colar AP antita CE2 AP Jenustal AP camostal nedium nedium

F





В

	VeroE6	HLT
Drugs	EC ₅₀ (μM)	
Cepharanthine	0.4	6.1
Quercitin	>100	78
Ergoloid	4.7	7.7
Ciclesonide	20.5	19.6
Licofelone	87.5	29.3
Hydroxychloroquine	1.58	9.2
Ivermectin	13.9	12.4
Hypericin	1.2	0.37
Vidarabine	>100	66
Celecoxib	13	~25

С

	VeroE6	HLT
Drugs	СС ₅₀ (μМ)	
Cepharanthine	22.3	13.8
Quercitin	>100	>100
Ergoloid	18.6	~87.7
Ciclesonide	>100	>100
Licofelone	>100	29.4
Hydroxychloroquine	>100	>100
Ivermectin	20.23	>100
Hypericin	4.8	0.13
Vidarabine	>100	>100
Celecoxib	13	>100







В


	VeroE6	HLT	
Drugs	EC ₅₀ (EC ₅₀ (μM)	
Eriodictyol	no effect	90	
Luteolin	~70.7	no effect	
Camostat	no effect	2.7	
Phenformin	no effect	~22.45	
Sulindac	no effect	>100	
Valaciclovir	no effect	>100	

2			
	VeroE6	HLT	
Drugs	CC ₅₀ (µ	СС ₅₀ (µМ)	
Eriodictyol	>100	>100	
Luteolin	>100	>100	
Camostat	>100	>100	
Phenformin	>100	>100	
Sulindac	>100	>100	
Valaciclovir	>100	>100	


Figure 5







Log [drug], μM



В

